Investors / Netherlands / Forbion
Forbion
Venture capital · Naarden, Netherlands · Europe
Forbion is a venture capital firm that invests in biotech companies across all stages of pharmaceutical drug development. It also runs a BioEconomy strategy investing in companies using biotechnology for food, agriculture, materials and environmental technologies.
Invests inHealthcare & Biotech
In its own wordsbiotechlife sciencestherapeuticsbioeconomyagrifoodsustainability
Your fit with Forbion
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsForbion lists 26 checked portfolio companies on its own site and is named in 29 funding rounds, 10 of them as lead. Its most frequent entry is Series A, 54% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 62% of its companies are based in United States. It invests most often alongside RA Capital, Frazier Life Sciences and Sanofi Ventures.
Counts come from funding rounds that name Forbion, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 54% |
| Series B | 19% |
| Growth | 27% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 12 | 4 |
| '26 | 17 | 6 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 62th | 26 companies |
| Recent activity | 98th | 19 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 84th | 6 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 10 |
| Frazier Life Sciences | 5 |
| Sanofi Ventures | 5 |
| Venrock | 4 |
| GV | 3 |
| Logos Capital | 3 |
| Oxford Science Enterprises | 3 |
| Sofinnova Partners | 3 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers26100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Forbion head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Forbion| Date | Company | Stage |
|---|---|---|
| 15 Oct 2026 | Series C+ Led | |
| 16 Sept 2026 | Series C+ Led | |
| 9 Sept 2026 | Series A | |
| 19 Aug 2026 | Series A | |
| 5 Aug 2026 | Series B | |
| 24 Jun 2026 | Series A | |
| 22 Jun 2026 | Series A | |
| 20 May 2026 | Series A |
Round details for Forbion
Amounts, full round histories and every co-investor in Forbion's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
26 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Nov 2025Series B | Funding round | |||
| Altesa BioSciences is developing a medicine to treat rhinovirus infections in chronic lung diseases such as COPD and asthma | Healthcare & Biotech | Feb 2026Series B | Funding round | |
| Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | Healthcare & Biotech | Feb 2026Series C+ | Funding round | |
| Beacon Therapeutics is a biotechnology company that develops gene therapies for ocular diseases | Healthcare & Biotech | Jan 2026Series C+ | Funding round | |
| Bionyra Pharma is a clinical-stage biopharmaceutical company developing antibody therapies for immune-mediated inflammatory diseases such as atopic dermatitis and inflammatory bowel disease. | Healthcare & Biotech | Jun 2026Series A | Funding round | |
| The company is developing a treatment for hypertrophic cardiomyopathy | Healthcare & Biotech | Nov 2025Series A | Funding round | |
| cAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing oral medicines for inflammatory diseases | Healthcare & Biotech | May 2026Series A | Funding round | |
| CellCentric develops a drug called inobrodib for the treatment of multiple myeloma and other cancers | Healthcare & Biotech | May 2025Series C+ · 2 rounds | Funding round | |
| Corsera Health is predicting and preventing cardiovascular disease before it begins. | Healthcare & Biotech | Jan 2026Series A | Funding round | |
| Apr 2026Series A | Funding round | |||
| Elevara Medicines develops treatments for rheumatoid arthritis | Healthcare & Biotech | Oct 2025Series A | Funding round | |
| Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases | Healthcare & Biotech | Oct 2025Series A · 2 rounds | Funding round | |
| GateBioscience develops small molecule drugs to eliminate harmful extracellular proteins that cause diseases. | Healthcare & Biotech | Nov 2025Series B | Funding round | |
| Aug 2026Series A | Funding round | |||
| MapLight Therapeutics develops innovative therapeutics for brain disorders using a unique discovery platform combining cutting-edge technologies. | Healthcare & Biotech | Jul 2025Series C+ | Funding round | |
| Mestag Therapeutics develops new therapies for cancer and inflammatory diseases by targeting fibroblast immunology | Healthcare & Biotech | Mar 2026Round | Funding round | |
| Mosanna Therapeutics is developing a nighttime nasal spray to help restore the body's natural airway control for obstructive sleep apnea treatment | Healthcare & Biotech | Jun 2025Series A | Funding round | |
| Omass Therapeutics harnesses proprietary biochemistry, native mass spectrometry and custom chemistry to interrogate targets and their interactions with their native ecosystem. | Healthcare & Biotech | Oct 2026Series C+ | Funding round | |
| Protego Bio is a clinical-stage biotechnology company developing small molecule therapies for protein misfolding diseases, including AL amyloidosis. | Healthcare & Biotech | Dec 2025Series B | Funding round | |
| RQ Bio discovers and develops long-acting monoclonal antibodies against seasonal influenza | Healthcare & Biotech | Jun 2026Series A | Funding round |
About this data
site last read 5 Nov 2026- Site
- forbion.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 9 Jan 2025
- Companies checked
- 26
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Forbion's profile as data
Pull Forbion's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/forbion.com
# also
GET /v1/firms/forbion.com/portfolio
GET /v1/firms/forbion.com/coinvestors
GET /v1/firms/forbion.com/news